KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Depreciation & Amortization (CF) (2016 - 2025)

Rigel Pharmaceuticals (RIGL) has 16 years of Depreciation & Amortization (CF) data on record, last reported at $601000.0 in Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) changed 0.5% year-over-year to $601000.0; the TTM value through Dec 2025 reached $2.4 million, up 8.39%, while the annual FY2025 figure was $2.4 million, 8.39% up from the prior year.
  • Depreciation & Amortization (CF) reached $601000.0 in Q4 2025 per RIGL's latest filing, roughly flat from $603000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $613000.0 in Q2 2024 and bottomed at $237000.0 in Q1 2022.
  • Average Depreciation & Amortization (CF) over 5 years is $402050.0, with a median of $326500.0 recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): decreased 29.7% in 2022, then surged 109.25% in 2024.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $404000.0 in 2021, then dropped by 29.7% to $284000.0 in 2022, then rose by 3.17% to $293000.0 in 2023, then soared by 106.14% to $604000.0 in 2024, then dropped by 0.5% to $601000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $601000.0 in Q4 2025, $603000.0 in Q3 2025, and $607000.0 in Q2 2025.